文献速递肿瘤 PET/CT

[18F]FAPI PET/CT 评估 [18F]FDG 非亲和性局灶性肝病变

[18F]FAPI PET/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-11-08

这项前瞻性研究纳入37例患者共80个[18F]FDG PET/CT非亲和性局灶性肝病变,行[18F]FAPI PET/CT。视觉分析检测肝脏恶性肿瘤的灵敏度96.0%、特异度58.3%、准确率83.8%。肝恶性肿瘤的SUVmax和LBR显著高于良性非炎性病变,但HCC与炎性病变的SUVmax无显著差异。

要点

  • [18F]FAPI PET/CT检测[18F]FDG非亲和性肝脏恶性肿瘤灵敏度达96.0%。
  • 肝恶性肿瘤SUVmax和LBR显著高于良性非炎性病变。
  • HCC与炎性病变SUVmax无显著差异,但HCC的LBR显著更低。

核心结论

  • [18F]FAPI PET/CT在检测[18F]FDG非亲和性HCC和非HCC恶性肿瘤方面显示高灵敏度。
  • [18F]FAPI可能是鉴别良性非炎性局灶性肝病变与[18F]FDG非亲和性肝脏恶性肿瘤的有前景的放射性药物。

研究设计与样本

  • 前瞻性研究,2021年1月至2022年3月纳入37例患者共80个[18F]FDG PET/CT非亲和性局灶性肝病变,均行[18F]FAPI PET/CT。
  • 所有病变经活检或随访确认,分为四个亚组:20个肝细胞癌(HCC)、5个非HCC恶性肿瘤、4个炎性病变、8个良性非炎性病变。

主要发现

  • 患者基线:37例入组参与者中34例男性,中位年龄57岁(范围48-67岁)。
  • 基于患者的视觉分析检测肝脏恶性肿瘤的灵敏度96.0%(24/25)、特异度58.3%(7/12)、准确率83.8%(31/37)。
  • 半定量分析:肝恶性肿瘤(33个HCC病灶;19个非HCC恶性病灶)的SUVmax和LBR显著高于11个良性非炎性病变[HCC:SUVmax 6.4 vs 4.5,P=0.017;LBR 5.1 vs 1.5,P=0.003;非HCC:SUVmax 5.5 vs 4.5,P=0.008;LBR 4.4 vs 1.5,P=0.042]。
  • 33个HCC病灶与17个炎性病变的SUVmax无显著差异(6.4 vs 8.2,P=0.37),但HCC的LBR显著低于炎性病变(5.1 vs 9.1,P=0.003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This prospective study was aimed to investigate the potential utility of [18F]fibroblast activation protein inhibitor (FAPI) PET/CT for evaluating focal liver lesions (FLLs) with [18F]FDG non-avidity. METHODS: From January 2021 to March 2022, this prospective study included 80 FLLs that were not avid on [18F]FDG PET/CT from 37 patients, then underwent [18F]FAPI PET/CT. All patients with FLL(s) with biopsy-proof or follow-up confirmation were categorized into four subgroups (20 hepatocellular carcinomas [HCCs]/5 non-HCC malignancies/4 inflammatory FLLs/8 benign noninflammatory FLLs). The diagnostic value of [18F]FAPI for detecting liver malignancy was determined by visual evaluation. Differences in the maximum standardized uptake value (SUVmax) and lesion-to-background ratio (LBR) obtained from [18F]FAPI PET/CT among the four subgroups were analyzed by semiquantitative analysis. RESULTS: Among the thirty-seven enrolled participants (34 males; median age 57 years, range 48-67 years), on visual evaluation, the sensitivity, specificity, and accuracy of [18F]FAPI PET for detecting liver malignancy in the patient-based analysis were 96.0% (24/25), 58.3% (7/12), and 83.8% (31/37), respectively. On semiquantitative analysis, the SUVmax and LBR of [18F]FAPI PET in liver malignancy (33 HCC lesions; 19 non-HCC malignant lesions) were significantly higher than those in 11 benign noninflammatory FLLs [HCC: SUVmax: 6.4 vs. 4.5, P = 0.017; LBR: 5.1 vs. 1.5, P = 0.003; non-HCC: SUVmax: 5.5 vs. 4.5, P = 0.008; LBR: 4.4 vs. 1.5, P = 0.042]. Notably, there was no significant difference in the SUVmax of [18F]FAPI PET between 33 HCC lesions and 17 inflammatory FLLs (6.4 vs. 8.2, P = 0.37), but the LBR of [18F]FAPI PET in HCC were significantly lower than that in inflammatory FLLs (5.1 vs. 9.1, P = 0.003). CONCLUSIONS: [18F]FAPI PET/CT shows high sensitivity in detecting HCC and non-HCC malignancy with [18F]FDG non-avidity. [18F]FAPI might be a promising radiopharmaceutical for the differential diagnosis of benign noninflammatory FLLs and liver malignancy with [18F]FDG non-avidity.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang J, He Q, Jiang S, et al. [18F]FAPI PET/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity. Eur J Nucl Med Mol Imaging. 2022. PMID: 36346437. doi:10.1007/s00259-022-06022-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。